Comorbidity of syndrome of increased epithelial permeability

Abstract

Syndrome of increased epithelial permeability is one of the most studied pathogenic syndromes in the 21st century. In the English literature, the term “the leaky gut syndrome” is widely used to refer to Syndrome of increased epithelial permeability. The participation of Syndrome of increased epithelial permeability in the development of diseases and pathological conditions of the gastrointestinal tract, as well as the pathology of other organs and systems, is widely discussed. In early 2021, the first multidisciplinary national consensus “Syndrome of increased epithelial permeability in clinical practice” was published, and in 2022, practical recommendations for physicians were published on one of the topical aspects of Syndrome of increased epithelial permeability – epithelial protective therapy. Of the epithelial protectors used in gastroenterology, only rebamipide has a universal positive effect on the barrier function of the gastrointestinal tract throughout its entire length and at three structural levels (preepithelial, epithelial, and subepithelial). As part of the review, experimental and clinical studies, systematic reviews on Syndrome of increased epithelial permeability and the use of rebamipide, published in domestic and foreign literature in 2022, were considered. Separately, the issues of the use of rebamipide in diseases of the cardiovascular system, its protective effect and the ability to level possible problems associated with drug therapy in terms of increasing its safety in the practice of internists (cardiologist and therapist) and surgeons (cardiac surgeon and vascular surgeon) are considered. The data presented in the review demonstrate the comorbidity of the Syndrome of increased epithelial permeability, which takes a certain part in the development of diseases not only of the digestive system, but also of non-gastroenterological diseases, in particular, the pathology of the cardiovascular system, which suggests the formation of new therapeutic strategies, the use of which will improve the clinical prognosis.

Keywords

• syndrome of increased epithelial permeability
• comorbidity
• epithelium-protective therapy
• rebamipide
• gastroenterology
• cardiology
• cardiovascular diseases
• antithrombotic therapy
• drug therapy safety